Thursday, May 28, 2020 4:19:06 PM
Posted by ABMN Staff on May 28th, 2020 // No Comments
Unum Therapeutics logoUnum Therapeutics Inc (NASDAQ:UMRX) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.88.
Several equities research analysts have recently weighed in on the stock. Morgan Stanley downgraded shares of Unum Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 3rd. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Friday, March 6th. Wedbush reissued a “hold” rating and issued a $1.00 target price on shares of Unum Therapeutics in a research report on Sunday, March 29th. Finally, HC Wainwright dropped their target price on shares of Unum Therapeutics from $18.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, March 27th.
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM